Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer
Clinical trial NCT05116085 · COMPLETED
Trial details
- NCT number
- NCT05116085
- Sponsor
- BeiGene
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-26
- Primary completion
- 2023-09-26
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.